Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Current Oncology (Toronto, Ont.)|July 25, 2025
HIV Integration into the PTEN Gene and Its Tumor Microenvironment Implications for Lung CancerDavey M Smith, Elizabeth F Rowland, Sara Gianella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or LymphomasJason J Luke, Randy F Sweis, J Randolph Hecht, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancerByoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, et al.
Breast (Edinburgh, Scotland)|January 5, 2019
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytesNancy Tray, Jessica Taff, Baljit Singh, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
Cancer|April 21, 2021
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohortSandip Pravin Patel, Edward Mayerson, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid TumorsBonnie S Glisson, Rom S Leidner, Robert L Ferris, et al.
Nature Communications|May 20, 2026
microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3Zhouting Zhu, Wenyan Han, Yufei Deng, et al.
Nature|March 28, 2020
Microbiome analyses of blood and tissues suggest cancer diagnostic approachGregory D Poore, Evguenia Kopylova, Qiyun Zhu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief ReportDong-Wan Kim, Sang-We Kim, D Ross Camidge, et al.
Pageof 6